Your browser does not support Javascript
email@mymsaa.org
Multiple Sclerosis Association of America Logo
Link to FaceBook Link to Twitter Link to YouTube Link to Pinterest
Register Why Register Contact MSAA Site Preferences Print Page Home
Improving Lives Today!
Donate Button
MS News
MS in the News
News From MSAA
MS Research Update



Home > News from MSAA > Highlights from the American Academy of Neurology's Annual Meeting

Highlights from the American Academy of Neurology's Annual Meeting

May 8, 2013

The American Academy of Neurology's (AAN) 65th Annual Meeting took place in San Diego, California in March. This large medical conference presents the latest findings in research and treatments for neurological conditions, including multiple sclerosis (MS). To follow are some important highlights.

General Studies

Adherence to a disease-modifying therapy (DMT) medication reduces the risk of MS relapses by 50 percent while increasing the number of individuals who are relapse-free at two years.

Women with MS who have had children may experience a slower rate of disability progression than women who have never been pregnant. More studies are needed to confirm these findings, and other disease factors may play a role in whether or not a patient becomes pregnant.

The herpes zoster vaccine (HZV) effect in MS was studied in 19 MS patients. These patients suffered no increase in MRI damage, nor had any clinical indication of increased MS symptoms at three months after the vaccination. This study suggests that the HZV is safe to use in MS patients.

FDA-Approved Disease-Modifying Therapies for MS

PEGylated Interferon beta-1a (peginterferon beta-1a) is a chemical modification of the interferon beta-1a (Avonex) molecule that allows it to be given subcutaneously (under the skin) every two or four weeks, in contrast to the current once-a-week, deeper, intramuscular injection. Studies are testing this experimental therapy for safety and effectiveness. If approved by the FDA, this would give patients the option of using a single-dose auto-injector with a prefilled syringe less frequently.

In a previous study (BENEFIT trial), patients with clinically isolated syndrome (CIS) were treated with Betaseron® (interferon beta-1b) or placebo for two years or until they were diagnosed with clinically definite MS (CDMS), at which time everyone was switched to Betaseron. A follow-up extension study at eight years showed both groups had stable or low disability levels, although the patients treated immediately with Betaseron following CIS had fewer relapses than those with delayed treatment.

The FDA-approved dose of Copaxone® (glatiramer acetate) is 20 mg given daily via subcutaneous injection. In this GALA study, patients received either a 40-mg dose three times per week subcutaneously, or a placebo. This experimental dose reduced relapses and MRI lesions compared to placebo. If FDA approved, a less-frequent treatment option for Copaxone may become available.

Rebif® (interferon beta-1a) is being studied with the use of the RebiSmart™ injection device, which is an electronic autoinjector that monitors drug adherence through an electronic dosing log. In a German study, it was found to have a 97-percent adherence rate at three months from the initiation of auto-injector use.

Data on small numbers of women who became pregnant within 90 days of taking Tysabri® (natalizumab) did not suggest any adverse effects on pregnancy outcome. The "C" recommendation (potential harm during pregnancy) stands. Women are not recommended to get pregnant while on Tysabri.

The higher dose (14 mg) of oral Aubagio® (teriflunomide) reduced both relapse rate and disability, while the 7-mg dose reduced relapses but not disability. Patients with fewer relapses prior to treatment had less disability while taking Aubagio.

A four-year patient-safety study with oral Gilenya® (fingolimod) showed no unexpected safety concerns, as well as a suggestion that disability may improve at four years on treatment. Those who switched to Gilenya prior to 12 weeks of discontinuing Tysabri, had a lower risk of relapsing than those who began therapy with Gilenya after 12 weeks of stopping Tysabri.

A combined analysis of the two Tecfidera™ (dimethyl fumarate, BG-12) clinical trials showed that when given twice per day, Tecfidera reduced relapses and disability, while also having an acceptable safety profile. A higher number of patients were free of disease activity versus placebo-treated patients over the two-year trial periods.

Experimental MS Therapies

In a three-year extension study of the oral drug Laquinimod, treated patients continued to have less risk of disability compared to placebo. Also, no new safety issues occurred.

Lemtrada® (alemtuzumab), a drug infused intravenously only three-to-five consecutive days for the entire first year, was more effective than Rebif in reducing overall disease activity. Adverse events, including thyroid and platelet problems, were consistent with previous studies.

Daclizumab (also known as Zenapax®), a monoclonal antibody given by injection, was shown to have less disease and MRI activity compared to placebo at one year. In the SELECT study, participants who were given a 24-week washout period (without treatment), and then reinitiated the drug, showed no evidence of rebound disease activity following the washout period.

MS patients on Ocrelizumab, a B-cell targeted monoclonal antibody, had low disease and MRI activity, which lasted at least 72 weeks after the last dose. No new safety concerns were experienced.

Vitamin D continues to be linked to MS and optic neuritis. Treatment with Vitamin D demonstrates positive immune-system changes with decreased inflammation and demyelination. African Americans with MS tend to have lower Vitamin D levels and more MS disability.

Studies in Progressive Types of MS

Fourteen primary-progressive MS (PPMS) patients were involved in clinical trials with the oral drug Amiloride, a potassium-sparing diuretic that may have neuroprotective activity. Preliminary results suggest positive effects on MRI and disability.

INFORMS is a double-blind, multicenter, study that will evaluate Gilenya® (fingolimod) 0.5 mg versus placebo in PPMS patients, over a flexible duration of three-to-five years. It will measure the time-to-sustained disability progression. The enrollment of 969 PPMS patients was completed in 2011.

A preliminary study with secondary-progressive MS (SPMS) patients evaluated the effectiveness of the oral statin drug, simvastatin. Preliminary results showed a positive influence on MRI and clinical disability outcomes. Further studies are necessary to confirm these results.

Siponimod (BAF312) is an oral drug that is in the same class of drugs as Gilenya, but it is not identical. A large study designed for SPMS patients is underway. A smaller study in relapsing-remitting MS (RRMS) was encouraging, based on relapse and MRI results.

Other Interesting Papers

High dietary salt was implicated in increased autoimmune neuro-inflammation by markedly boosting a Th17 helper T-cell driven autoimmune response in EAE (an experimental disease similar to MS in mice). Th17 is an immune-system cell (lymphocyte) involved with the inflammation that causes damage to the myelin and nerves with MS. This Th17-boosting property of dietary salt is also seen in humans. The theory that salt may increase MS inflammation has far reaching practical dietary implications for MS patients.

Glucose levels (sugar levels in the blood) were found to be a predictor of the level of disability in MS patients. Further studies are needed to prove a causal relationship.

MS patients who smoke have an increased severity of MS. Reasons include the fact that smoking causes damaging changes in the immune system and blood pressure regulating system.

MS patients with certain genetic patterns (HLA-DRB1) have an increased level of spinal cord damage compared to MS patients without HLA-DRB1. This highlights the value of examining the brain and spinal cord with a microscope and linking findings to genetic factors.

Chronic Cerebrospinal Venous Insufficiency (CCSVI) has been proposed to cause MS damage due to blocked venous drainage from the brain. In this study, no difference was found in the proportion of MS patients with CCSVI compared to healthy people without MS. This study suggests that CCSVI is not more common in MS patients than in the general population.

Walking and gait were measured in MS patients on Ampyra™ (dalfampridine) while first taking Ampyra, then while not on the drug, and again after the drug was reinstated. Researchers found that walking became worse for patients when not taking the drug, and improved when Ampyra was reinstated.

Please see MSAA's MS Research Update for additional details on the FDA-approved disease-modifying therapies, experimental treatments, and other MS research. For more information or to speak with a trained Helpline consultant please call MSAA at (800) 532-7667. Questions to MSAA’s Client Services Department may be emailed to MSquestions@mymsaa.org.

Written by Jack Burks, MD, MSAA Chief Medical Officer
Edited by Susan Wells Courtney, MSAA Senior Writer and Creative Director

Last Updated on Wednesday, 08 May 2013 13:26